By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Fresh data on Heart Disorders and Diseases - Acute Myocardial Infarction are presented in a new report. According to news reporting out of Gwangju, South Korea, by NewsRx editors, research stated, “Although there have been several reports that prasugrel can improve clinical outcomes, the efficacy and safety of prasugrel is unknown in Korean patients with acute myocardial infarction (AMI) undergoing successful revascularization. A total of 4421 patients [637 patients were prescribed prasugrel (60/10 or 5 mg, loading/maintenance dose) and 3784 patients clopidogrel (600 or 300/75 mg)] with AMI undergoing successful revascularization were enrolled from the core clinical cohort of Korea Acute Myocardial Infarction Registry-National Institute of Health.”
Financial supporters for this research include Chosun University Hospital, Research of Korea Centers for Disease Control and Prevention, Korean Health Technology R&D Project, Ministry of Health & Welfare.
Our news journalists obtained a quote from the research from Chonnam National University Hospital, “After propensity score matching (637 pairs), there were no significant differences in baseline clinical and procedural characteristics and in-hospital medications between the two groups. The primary efficacy endpoint, defined as the composite of cardiac death, MI, stroke, or target vessel revascularization at 6 months showed no significant difference between prasugrel and clopidogrel (2.4% vs. 2.9%, p = 0.593). Also, no difference was observed in the composite of cardiac death, MI, or stroke during hospitalization between two groups (0.8% vs. 0.9%, p = 0.762). However, the incidence of in-hospital Thrombolysis in Myocardial Infarction (TIMI) major or minor bleeding was significantly higher in prasugrel compared with clopidogrel (5.3% vs. 2.7%, p = 0.015). In multivariate linear regression analysis, trans-femoral intervention, use of glycoprotein Ilb/Illa inhibitors, use of calcium channel blocker, and use of prasugrel were independent predictors of in-hospital TIMI major or minor bleeding [odds ratio (OR) = 6.918; 95% confidence interval (CI) = 2.453-19.510, OR = 2.577; 95% CI = 1.406-4.724, OR = 4.016; 95% CI = 1.382-11.668, OR = 2.022; 95% CI = 1.101-3.714]. Our study shows that the recommended dose of prasugrel had significantly higher in hospital bleeding complications without reducing ischemic events compared with clopidogrel.”
According to the news editors, the research concluded: “However, further large-scale, long-term, randomized clinical trials are required to accurately assess the efficacy and safety of prasgurel and to find out the optimal dose for Korean AMI patients.”
For more information on this research see: Comparison of prasugrel versus clopidogrel in Korean patients with acute myocardial infarction undergoing successful revascularization. Journal of Cardiology , 2018;71(1-2):36-43. Journal of Cardiology can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; Journal of Cardiology - http://www.journals.elsevier.com/journal-of-cardiology/)
Our news journalists report that additional information may be obtained by contacting M.H. Jeong, Chonnam Natl Univ Hosp, Gwangju 501757, South Korea. Additional authors for this research include K.H. Park, H.K. Kim, T.H. Ahn, K.B. Seung, D.J. Oh, D.J. Choi, H.S. Kim, H.C. Gwon, I.W. Seong, K.K. Hwang, S.C. Chae, K.B. Kim, Y.J. Kim, K.S. Cha, S.K. Oh and J.K. Chae.
The direct object identifier (DOI) for that additional information is: https://doi.org/10.1016/j.jjcc.2017.05.003. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2018, NewsRx LLC
CITATION: (2018-04-28), Reports from Chonnam National University Hospital Add New Data to Findings in Acute Myocardial Infarction (Comparison of prasugrel versus clopidogrel in Korean patients with acute myocardial infarction undergoing successful revascularization), Obesity, Fitness & Wellness Week, 3292, ISSN: 1532-4664, BUTTER® ID: 015543015
From the newsletter Obesity, Fitness & Wellness Week.
https://www.newsrx.com/Butter/#!Search:a=15543015
This is a NewsRx® article created by NewsRx® and posted by NewsRx®. As proof that we are NewsRx® posting NewsRx® content, we have added a link to this steemit page on our main corporate website. The link is at the bottom left under "site links" at https://www.newsrx.com/NewsRxCorp/.
We have been in business for more than 20 years and our full contact information is available on our main corporate website.
We only upvote our posts after at least one other user has upvoted the article to increase the curation awards of upvoters.
NewsRx® offers 195 weekly newsletters providing comprehensive information on all professional topics, ranging from health, pharma and life science to business, tech, energy, law, and finance. Our newsletters report only the most relevant and authoritative information from qualified sources.